Pulmonary hypertension in advanced chronic obstructive pulmonary disease

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 2, 2012, Pages 138-143

  Orr, Randy ^a   Smith, Lewis J ^a   Cuttica, Michael J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

6 min walk distance; chronic obstructive pulmonary disease; pulmonary hypertension

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; HUMAN; HYPOXEMIA; HYPOXIA; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PREVALENCE; PULMONARY HYPERTENSION; REVIEW; VASOCONSTRICTION;

ADRENAL CORTEX HORMONES; ANOXIA; DISEASE PROGRESSION; FEMALE; HOSPITALIZATION; HUMANS; HYPERTENSION, PULMONARY; MALE; OXYGEN INHALATION THERAPY; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UNITED STATES;

EID: 84856643843     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32834f2093     Document Type: Review

References (47)

1. Han MK, McLaughlin VV, Criner GJ, et al. Pulmonary diseases and the heart. Circulation 2007; 116:2992-3005. (Pubitemid 350291207)
2. Herzog R, Cunningham-RundlesS.Immunologic impactofnutrient depletion in chronic obstructivepulmonarydisease. Curr DrugTargets 2011;12:489-500.
3. Vondracek SF, Voelkel NF, McDermott MT, et al. The relationship between adipokines, body composition, and bone densityinmen with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2009; 4:267-277.
4. de Torres JP, Bastarrika G, Zagaceta J, et al. Emphysema presence, severity, and distribution has little impact on the clinical presentation of a cohort of patients with mild to moderate COPD. Chest 2011; 139:36-42.
5. Cho MH, Washko GR, Hoffmann TJ, et al. Cluster analysis in severe emphysema subjects using phenotype and genotype data: an exploratory investigation. Respir Res 2010; 11:30.
6. Garcia-Aymerich J, Gomez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011; 66:430-437.
7. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-555. (Pubitemid 47403272)
8. Papaioannou AI, Loukides S, Gourgoulianis KI, et al. Global assessment of the COPD patient: time to look beyond FEV1? Respir Med 2009; 103:650-660.
9. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182:598-604.
10. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (1 Suppl):S43-54.
11. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (1 Suppl): S55-S66.
12. Scharf SM, Iqbal M, Keller C, et al. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002; 166:314-322. (Pubitemid 34864419)
13. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127:1531-1536. (Pubitemid 46218776)
14. Cuttica MJ, Kalhan R, Shlobin OA, et al. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med 2010; 104:1877-1882.
15. Hoeper MM, Barbera JA, Channick RN, et al. Diagnosis, assessment, and treatment of nonpulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009; 54 (1 Suppl):S85-S96.
16. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy; importance of pulmonary artery pressure. Chest 1995; 107:1193-1198.
17. Stone AC, Machan JT, Mazer J, et al. Echocardiographic evidence of & pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease. Lung 2011; 189:207-212.
18. Kessler R, Faller M, Fourgaut G, et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159:158-164. (Pubitemid 29036519)
19. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167:735-740. (Pubitemid 36801751)
20. Fisher MR, Criner GJ, Fishman AP, et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 2007; 30:914-921. (Pubitemid 351194795)
21. Higham MA, Dawson D, Joshi J, et al. Utility of echocardiography in assessment of pulmonary hypertension secondary to COPD. Eur Respir J 2001; 17:350-355. (Pubitemid 32600600)
22. Pynnaert C, Lamotte M, Naeije R. Aerobic exercise capacity in COPD patients & with and without pulmonary hypertension. Respir Med 2010; 104:121-126.
23. Sims MW, Margolis DJ, Localio AR, et al. Impact of pulmonary artery pressure on exercise function in severe COPD. Chest 2009; 136:412
24. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172:189-194. (Pubitemid 40981192)
25. Swiston JR, Johnson SR, Granton JT. Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature. Respir Med 2010; 104:1588-1607.
26. Timms RM, Khaja FU, Williams GW. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med 1985; 102:29-36. (Pubitemid 15187651)
27. Weitzenblum E, Sautegeau A, Ehrhart M, et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131: 493-498. (Pubitemid 15086729)
28. Wright JL, Petty T, Thurlbeck WM. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung 1992; 170:109-124.
29. Magee F, Wright JL, Wiggs BR, et al. Pulmonary vascular structure and function in chronic obstructive pulmonary disease. Thorax 1988; 43:183-189. (Pubitemid 18086542)
30. Santos S, Peinado VI, Ramirez J, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002; 19:632-638. (Pubitemid 34285159)
31. Seimetz M, Parajuli N, Pichl A, et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 2011; 147:293-305.
32. Walter RE, Wilk JB, Larson MG, et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008; 133:19-25.
33. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59:574-580. (Pubitemid 38901515)
34. Chaouat A, Savale L, Chouaid C, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009; 136:678-687.
35. Kwon YS, Chi SY, Shin HJ, et al. Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Korean Med Sci 2010; 25:1487-1491.
36. Ulrich S, Hersberger M, Fischler M, et al. Genetic polymorphisms of the & serotonin transporter, but not the 2a receptor or nitric oxide synthetase, are associated with pulmonary hypertension in chronic obstructive pulmonary disease. Respiration 2010; 79:288-295.
37. Eddahibi S, Chaouat A, Morrell N, et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003; 108:1839-1844. (Pubitemid 37296093)
38. Celli BR. Standards for the optimal management of COPD: a summary. Chest 1998; 113 (4 Suppl):283S-287S. (Pubitemid 28166891)
39. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest 2010; 137 (6 Suppl):39S-51S.
40. Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010; 181:270-278.
41. Rietema H, Holverda S, Bogaard HJ, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008; 31:759-764.
42. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32:619-628.
43. Valerio G, Bracciale P, Grazia D'Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2009; 3:15-21.
44. Archer SL, Mike D, Crow J, et al. A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 1996; 109:750-755. (Pubitemid 26086944)
45. Hegewald MJ, Elliott CG. Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension. Chest 2009; 135:536-537.
46. Dernaika TA, Beavin M, Kinasewitz GT. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 2010; 79:377-382.
47. Barbera JA, Roger N, Roca J, et al. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996; 347:436-440. (Pubitemid 26054069)